Verici Dx PLC (fra:63V) Share Price

Company Profile

Business description
Verici Dx PLC is an immuno-diagnostics development company. The company is focused on developing diagnostics technologies that will help understand the outcomes of an organ transplant surgery. There are two products for clinical validation and commercialization: Clarava, which is a pre-transplant prognosis for the risk of early acute rejection; and Tuteva, a post-transplant diagnostic focused upon acute cellular rejection including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatine levels. The business of the Group comprises a single activity, which of the development of prognostic and diagnostic tests for kidney transplant patients.
Contact
19 Stanwell Road
Avon House
Penarth
CardiffCF64 2EZ
GBR
T: +44 2920710570
https://www.vericidx.com
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2025
Employees
14

Recommended

These undervalued stocks of high-quality companies could be attractive investments today.

Margaret Giles | 17 March 2025

Ben Graham was the king of flipping deep value stocks. The best investment of his life came from something very different.

Joseph Taylor | 17 March 2025

These shares have surged in price in the last year but are significantly overvalued according to our analysts.

Morningstar | 16 March 2025

Index	Last price	Change	% Change
All Ordinaries	8,082.10	68.80	0.86%
CAC 40	8,063.33	35.05	0.44%
DAX 40	23,103.14	116.32	0.51%
Dow JONES (US)	41,668.36	180.17	0.43%
FTSE 100	8,674.58	42.25	0.49%
HKSE	24,145.57	185.59	0.77%
NASDAQ	17,800.78	46.70	0.26%
Nikkei 225	37,396.52	343.42	0.93%
NZX 50 Index	12,166.14	100.11	-0.82%
S&P 500	5,667.22	28.28	0.50%
S&P/ASX 200	7,854.10	64.40	0.83%
SSE Composite Index	3,426.13	6.57	0.19%